CoronaryAtlas logo
CoronaryAtlas
Proliferating Cell Nuclear Antigen
Pathway / Off-pathway / systemic markers

Proliferating Cell Nuclear Antigen

PCNAprotein

Proliferating cell nuclear antigen marks cellular proliferation in post-infarct healing but is off-pathway to atherothrombotic MI.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleGeneric cell-cycle marker; detected in peri-infarct region but not mechanistically on cascade.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
57
A — assay feasibility
68
E — evidence strength
18
T1DI (composite)
4
Specificity differential (R−C)-42.1
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 2
2hypovolemia / dehydrationmag 2
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 1
3sudden cardiac deathmag 1
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 7/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 14 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(1)